Drug
Denosumab (Prolia)
Denosumab (Prolia) is a pharmaceutical drug with 5 clinical trials. Currently 1 active trials ongoing. Historical success rate of 50.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
50.0%
Based on 1 completed trials
Completion Rate
50%(1/2)
Active Trials
1(20%)
Results Posted
100%(1 trials)
Terminated
1(20%)
Phase Distribution
Ph phase_3
2
40%
Ph phase_1
1
20%
Ph phase_4
2
40%
Phase Distribution
1
Early Stage
0
Mid Stage
4
Late Stage
Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 3Large-scale testing
2(40.0%)
Phase 4Post-market surveillance
2(40.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
50.0%
1 of 2 finished
Non-Completion Rate
50.0%
1 ended early
Currently Active
1
trials recruiting
Total Trials
5
all time
Status Distribution
Active(3)
Completed(1)
Terminated(1)
Detailed Status
Not yet recruiting2
Terminated1
Completed1
Active, not recruiting1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
1
Success Rate
50.0%
Most Advanced
Phase 4
Trials by Phase
Phase 11 (20.0%)
Phase 32 (40.0%)
Phase 42 (40.0%)
Trials by Status
not_yet_recruiting240%
terminated120%
completed120%
active_not_recruiting120%
Recent Activity
1 active trials
Showing 5 of 5
active_not_recruitingphase_1
NT-NOA - Novel Treatment of Some Men With Non-Obstructive Azoospermia
NCT06706414
not_yet_recruitingphase_3
RANKL Inhibition to Combat Sarcopenia in Hip Fracture Patients
NCT07056478
not_yet_recruitingphase_4
Efficacy of Romosozumab and Denosumab Combined Treatment in Postmenopausal Osteoporosis Patients with Multiple Fragility Fractures
NCT06720350
terminatedphase_4
The Efficacy of Denosumab in Incomplete Patients Spinal Cord Injury
NCT03029442
completedphase_3
Denosumab for Prevention of Osteoporosis in Renal Transplant Recipients
NCT01377467
Clinical Trials (5)
Showing 5 of 5 trials
NCT06706414Phase 1
NT-NOA - Novel Treatment of Some Men With Non-Obstructive Azoospermia
NCT07056478Phase 3
RANKL Inhibition to Combat Sarcopenia in Hip Fracture Patients
NCT06720350Phase 4
Efficacy of Romosozumab and Denosumab Combined Treatment in Postmenopausal Osteoporosis Patients with Multiple Fragility Fractures
NCT03029442Phase 4
The Efficacy of Denosumab in Incomplete Patients Spinal Cord Injury
NCT01377467Phase 3
Denosumab for Prevention of Osteoporosis in Renal Transplant Recipients
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5